Loading
A phase 3 trial testing BNT324 in prostate cancer, now recruiting.
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer is a phase 3 interventional study registered as NCT07365995, led by BioNTech SE with BioNTech (Shanghai) Pharmaceuticals and DualityBio, and recruiting on the registry. Official title: A Phase III, Randomised, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer. Planned enrolment is 736 participants (estimated). The study started in 2026-04-22 and primary completion is expected in 2031-02. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BNT324, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/